Additional positive data from pivotal aspen study of brensocatib in patients with bronchiectasis to be presented at the 7th world bronchiectasis conference

—new graph depicting 52-week fev1 data illustrate significantly less decline in lung function for brensocatib 25 mg versus placebo— —additional exploratory endpoints to be presented, including fvc and patient-reported best score—   bridgewater, n.j. , july 3, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that additional positive results from the aspen study, a global, randomized, double-blind, placebo-controlled phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis, will be presented tomorrow, july 4, 2024, at the 7th world bronchiectasis conference (wbc) in dundee, scotland.
INSM Ratings Summary
INSM Quant Ranking